Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Non-Current Liabilities: 2019-2025

Historic Other Non-Current Liabilities for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $679,000.

  • BridgeBio Pharma's Other Non-Current Liabilities rose 80.11% to $679,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $679,000, marking a year-over-year increase of 80.11%. This contributed to the annual value of $286,000 for FY2024, which is 94.92% down from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Other Non-Current Liabilities is $679,000, which was up 24.59% from $545,000 recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Other Non-Current Liabilities high stood at $28.6 million for Q2 2022, and its period low was $286,000 during Q4 2024.
  • In the last 3 years, BridgeBio Pharma's Other Non-Current Liabilities had a median value of $595,000 in 2024 and averaged $4.7 million.
  • In the last 5 years, BridgeBio Pharma's Other Non-Current Liabilities spiked by 315.16% in 2021 and then tumbled by 96.80% in 2024.
  • BridgeBio Pharma's Other Non-Current Liabilities (Quarterly) stood at $22.1 million in 2021, then increased by 20.73% to $26.6 million in 2022, then plummeted by 78.85% to $5.6 million in 2023, then crashed by 94.92% to $286,000 in 2024, then skyrocketed by 80.11% to $679,000 in 2025.
  • Its Other Non-Current Liabilities was $679,000 in Q3 2025, compared to $545,000 in Q2 2025 and $352,000 in Q1 2025.